Repligen Executive and Leadership Team

Olivier Loeillot, the Chief Executive Officer at Repligen, directs the company's overarching strategy and market positioning. Loeillot guides the executive team in developing and executing initiatives that advance bioprocessing technologies and solutions for biologic drug production. This leadership involves fostering innovation across all departments, ensuring alignment with the company's mission to inspire bioprocessing advances. The Chief Executive Officer's focus extends to expanding Repligen's global reach and solidifying its reputation as a leader in the life sciences sector. By championing strategic partnerships and driving operational excellence, Olivier Loeillot ensures the company consistently delivers high-value products and flexible solutions to meet the evolving needs of the biopharmaceutical industry.

Jason Garland, the Chief Financial Officer at Repligen, directs all financial operations and strategic fiscal planning for the company. Garland manages capital allocation, investor relations, and financial reporting, ensuring fiscal health and sustainable growth. This leadership position involves overseeing budgeting, forecasting, and risk management to support Repligen's development and commercialization of high-value bioprocessing products. The Chief Financial Officer's strategic insights are crucial for identifying investment opportunities and optimizing financial performance in the dynamic life sciences market. By maintaining rigorous financial discipline, Jason Garland enables the company to pursue its mission of inspiring advances in biologic drug production and delivering flexible solutions to its global clientele.

James Bylund, the Chief Operating Officer at Repligen, oversees the company's global operational execution and supply chain management. Bylund drives efficiency and scalability across manufacturing, logistics, and customer support functions, ensuring the reliable delivery of high-value bioprocessing products. This role is critical in translating strategic objectives into tangible operational outcomes, supporting the commercialization of solutions that address key steps in biologic drug production. The Chief Operating Officer's focus includes optimizing production processes, enhancing quality control, and fostering a culture of continuous improvement. By streamlining operations, James Bylund directly contributes to Repligen's mission of inspiring advances in bioprocessing and reinforcing its position as a trusted partner in the life sciences industry.

Keith Lee Lee Robinson, the Chief Information Officer at Repligen, architects the company's technology infrastructure and digital transformation strategies. Robinson oversees the implementation and management of critical IT systems that support Repligen's bioprocessing product development and commercialization efforts. This role involves ensuring robust cybersecurity measures and driving digital innovation to enhance operational efficiency and data integrity across the organization. The Chief Information Officer's responsibilities include leveraging technology to streamline workflows, improve data analytics capabilities, and support the company's mission of inspiring advances in bioprocessing. By optimizing the technological landscape, Keith Lee Lee Robinson enables seamless integration of high-value products and flexible solutions, directly impacting the production of biologic drugs.